Runx2 Antibody
Rabbit Polyclonal Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, IHC, FC |
---|---|
Host | Rabbit |
Clonality | Polyclonal |
Isotype | Rabbit IgG |
Positive Control | Western blot: CEM cell lysate, IHC: human tonsil tissue, FACS: NCI-H460 cells. |
---|---|
Application & Usage | Western blot: ~1:1000, IHC: 1:10 – 1:50, FACS: 1:10 – 1:50. |
Other Names | RUNX2; AML3; CBFA1; OSF2; PEBP2A; Runt-related transcription factor 2; Acute myeloid leukemia 3 protein; Core-binding factor subunit alpha-1; Oncogene AML-3; Osteoblast-specific transcription factor 2; Polyomavirus enhancer-binding protein 2 alpha A subunit; SL3-3 enhancer factor 1 alpha A subunit; SL3/AKV core-binding factor alpha A subunit |
Target/Specificity | Runx2 |
Antibody Form | Liquid |
Appearance | Colorless liquid |
Formulation | In PBS with 0.09% (W/V) sodium azide. |
Handling | The antibody solution should be gently mixed before use. |
Reconstitution & Storage | -20 °C |
Background Descriptions | |
Precautions | Runx2 Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The mammalian Runt-related transcription factor (RUNX) family comprises three members, RUNX1 (also designated AML-1, PEBP2åB, CBFA2), RUNX2 (also designated AML-3, PEBP2åA, CBFA1, Osf2) and RUNX3 (also designated AML-2, PEBPåC, CBFA3). RUNX family members are DNA-binding proteins that regulate the expression of genes involved in cellular differentiation and cell cycle progression. RUNX2 is essential for skeletal mineralization in that it stimulates osteoblast differentiation of mesenchymal stem cells, promotes chondrocyte hypertrophy and contributes to endothelial cell migration and vascular invasion of developing bones. Regulating RUNX2 expression may be a useful therapeutic tool for promoting bone formation. Mutations in the C-terminus of RUNX2 are associated with cleidocranial dysplasia syndrome, an autosomal-dominant skeletal dysplasia syndrome that is characterized by widely patent calvarial sutures, clavicular hypoplasia, supernumerary teeth, and short stature.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.